| Literature DB >> 32613444 |
Taylor Pindi Sala1, Mona Villedieu2, Laura Damian3, Jean-Charles Crave2, Vivien Pautot4, Ljudmila Stojanovich5, Jan Willem Cohen Tervaert6, Patrick Cherin7, Cristina Belizna8,9.
Abstract
The most common peripheral nervous system manifestations in Sjogren's syndrome are small fiber sensory neuropathies (SFPN) and axonal sensorimotor polyneuropathies. Currently, treatment in small fiber neuropathy is mainly symptomatic and based on anti-depressors and anti-epileptics. The benefit of treatment with polyvalent immunoglobulins for SFPN has been reported in small series of patients, although transient in several cases. The medium-to-long-term effects of polyvalent immunoglobulins (Ig) in SFPN in patients with Sjogren's syndrome who are refractory to conventional treatments remain an unmet medical need. We present our experience related to the persistent improvement of Ig in a case series of SFPN in Sjogren's syndrome and relevant data in the literature regarding the benefits of immunoglobulins, for this indication.Entities:
Keywords: Small fiber sensory neuropathies and sjögren syndrome; Small fiber sensory neuropathies and sjögren syndrome and treatment; Small fiber sensory neuropathies in sjögren syndrome and immunoglobulins; Small fiber sensory neuropathies in sjögren syndrome and intravenous immunoglobulins; Small fiber sensory neuropathies in sjögren syndrome and subcutaneous immunoglobulins
Mesh:
Substances:
Year: 2020 PMID: 32613444 DOI: 10.1007/s00415-020-10033-z
Source DB: PubMed Journal: J Neurol ISSN: 0340-5354 Impact factor: 4.849